Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Combating resistance in a challenging, changing environment.

Goldstein FW.

Clin Microbiol Infect. 2007 Jun;13 Suppl 2:2-6. Review.

2.

Comparison of Etest with agar dilution for testing the susceptibility of Pseudomonas aeruginosa and other multidrug-resistant bacteria to colistin.

Goldstein FW, Ly A, Kitzis MD.

J Antimicrob Chemother. 2007 May;59(5):1039-40. Epub 2007 Apr 16. No abstract available.

PMID:
17437963
3.

European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing.

Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Mouton JW, Odenholt I, Rodloff A, Soussy CJ, Steinbakk M, Soriano F, Stetsiouk O.

Clin Microbiol Infect. 2006 Jun;12(6):501-3.

4.

Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.

Kitzis MD, Goldstein FW.

Clin Microbiol Infect. 2006 Jan;12(1):92-5.

5.

[Shoulder arthritis due to Haemophilus aphrophilus].

Bouldouyre MA, Stawiarski N, Michon M, Nguyen Van JC, Ben-Ali A, Rajzbaum G, Goldstein FW.

Med Mal Infect. 2005 Jun;35(6):367-9. Review. French.

PMID:
15982845
6.

Useful oldies: oral antibiotics for the treatment of MRSA infections.

Zvethkova K, Laffeach P, Goldstein FW.

J Hosp Infect. 2004 Aug;57(4):348-9. No abstract available.

PMID:
15262399
7.

False synergy between vancomycin and beta-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods.

Goldstein FW, Atoui R, Ben Ali A, Nguyen JC, Ly A, Kitzis MD.

Clin Microbiol Infect. 2004 Apr;10(4):342-5.

8.

In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae.

Kitzis MD, Ly A, Goldstein FW.

Antimicrob Agents Chemother. 2004 Jan;48(1):366-7. No abstract available.

9.

Vancomycin-resistant Staphylococcus aureus: no apocalypse now.

Goldstein FW, Kitzis MD.

Clin Microbiol Infect. 2003 Aug;9(8):761-5.

10.

New Klebsiella oxytoca beta-lactamase genes bla(OXY-3) and bla(OXY-4) and a third genetic group of K oxytoca based on bla(OXY-3).

Granier SA, Leflon-Guibout V, Goldstein FW, Nicolas-Chanoine MH.

Antimicrob Agents Chemother. 2003 Sep;47(9):2922-8.

11.

European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria.

Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Mouton JW, Osterlund A, Rodloff A, Steinbakk M, Urbaskova P, Vatopoulos A.

J Antimicrob Chemother. 2003 Aug;52(2):145-8. Epub 2003 Jul 1. No abstract available.

PMID:
12837738
12.

Recognition of two genetic groups in the Klebsiella oxytoca taxon on the basis of chromosomal beta-lactamase and housekeeping gene sequences as well as ERIC-1 R PCR typing.

Granier SA, Plaisance L, Leflon-Guibout V, Lagier E, Morand S, Goldstein FW, Nicolas-Chanoine MH.

Int J Syst Evol Microbiol. 2003 May;53(Pt 3):661-8.

PMID:
12807183
13.
14.

Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation.

Goldstein FW.

Clin Microbiol Infect. 2002 Dec;8(12):823-5. No abstract available.

15.

False susceptibility of Klebsiella oxytoca to some extended-spectrum cephalosporins.

Granier SA, Nicolas-Chanoine MH, Nguyen Van JC, Leflon-Guibout V, Kitzis MD, Goldstein FW.

J Antimicrob Chemother. 2002 Aug;50(2):303-4. No abstract available.

PMID:
12161419
16.

The extended-spectrum K1 beta-lactamase from Klebsiella oxytoca SC 10,436 is a member of the bla(OXY-2) family of chromosomal Klebsiella enzymes.

Granier SA, Leflon-Guibout V, Nicolas-Chanoine MH, Bush K, Goldstein FW.

Antimicrob Agents Chemother. 2002 Jun;46(6):2056-7. No abstract available.

17.

First description of a TEM-30 (IRT-2)-producing Klebsiella oxytoca isolate.

Granier SA, Nguyen Van JC, Kitzis MD, Goldstein FW, Leflon-Guibout V, Nicolas-Chanoine MH.

Antimicrob Agents Chemother. 2002 Apr;46(4):1158-9. No abstract available.

18.

OXA-35 is an OXA-10-related beta-lactamase from Pseudomonas aeruginosa.

Aubert D, Poirel L, Ali AB, Goldstein FW, Nordmann P.

J Antimicrob Chemother. 2001 Nov;48(5):717-21.

PMID:
11679562
19.

Low-level resistance to fluoroquinolones among Salmonella and Shigella.

Nguyen JC, Goldstein FW.

Clin Microbiol Infect. 2000 Apr;6(4):231. No abstract available.

21.

Penicillin-resistant Streptococcus pneumoniae: selection by both beta-lactam and non-beta-lactam antibiotics.

Goldstein FW.

J Antimicrob Chemother. 1999 Aug;44(2):141-4. No abstract available.

PMID:
10473219
22.

In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.

Kitzis MD, Goldstein FW, Miegi M, Acar JF.

J Antimicrob Chemother. 1999 Jun;43 Suppl C:21-6.

PMID:
10404333
23.

Low rate of Clostridium difficile colonization in ambulatory and hospitalized HIV-infected patients in a hospital unit: a prospective survey.

Mainardi JL, Lacassin F, Guilloy Y, Goldstein FW, Leport C, Acar JF, Vildé JL.

J Infect. 1998 Sep;37(2):108-11.

PMID:
9821082
24.

Bloody diarrhea caused by Klebsiella pneumoniae: a new mechanism of bacterial virulence?

Guerin F, Le Bouguenec C, Gilquin J, Haddad F, Goldstein FW.

Clin Infect Dis. 1998 Sep;27(3):648-9. No abstract available.

PMID:
9770172
25.

[Broad-spectrum cephalosporins].

Goldstein FW.

Presse Med. 1998 Jul 4-11;27(24):1256-8. French. No abstract available.

PMID:
9767792
26.

Cat scratch disease due to Bartonella henselae serotype Marseille (Swiss cat) in a seronegative patient.

Mainardi JL, Figliolini C, Goldstein FW, Blanche P, Baret-Rigoulet M, Galezowski N, Fournier PE, Raoult D.

J Clin Microbiol. 1998 Sep;36(9):2800. No abstract available.

27.

Consequences of increasing resistance to antimicrobial agents.

Acar JF, Goldstein FW.

Clin Infect Dis. 1998 Aug;27 Suppl 1:S125-30. Review.

PMID:
9710681
28.

Carbapenems as inhibitors of OXA-13, a novel, integron-encoded beta-lactamase in Pseudomonas aeruginosa.

Mugnier P, Podglajen I, Goldstein FW, Collatz E.

Microbiology. 1998 Apr;144 ( Pt 4):1021-31.

PMID:
9579076
29.

30 years of penicillin-resistant S pneumoniae: myth or reality?

Goldstein FW, Garau J.

Lancet. 1997 Jul 26;350(9073):233-4. No abstract available.

PMID:
9242797
30.

[Stability of the ceftriaxone spectrum].

Goldstein FW.

Presse Med. 1997 Feb 8;26(3):120-1. French. No abstract available.

PMID:
9082430
31.

Multiple intracranial tuberculomas in a non-immunocompromised patient.

De Jonghe B, Michard F, Petit E, Mainardi JL, Goldstein FW, Garrouste M, Misset B.

Clin Microbiol Infect. 1997;3(5):574-576. No abstract available.

32.
33.

Trends in bacterial resistance to fluoroquinolones.

Acar JF, Goldstein FW.

Clin Infect Dis. 1997 Jan;24 Suppl 1:S67-73. Review.

PMID:
8994781
34.

Highlights of the French Antimicrobial Resistance Surveillance Project. French Study Group.

Péan Y, Goldstein FW, Guerrier ML.

Diagn Microbiol Infect Dis. 1996 Aug;25(4):191-4.

PMID:
8937843
35.

Relevance of the Alexander Project: pharmacodynamic considerations.

Drusano GL, Goldstein FW.

J Antimicrob Chemother. 1996 Jul;38 Suppl A:141-54.

PMID:
8858480
37.

Mortality of nosocomial pneumonia in ventilated patients: influence of diagnostic tools.

Timsit JF, Chevret S, Valcke J, Misset B, Renaud B, Goldstein FW, Vaury P, Carlet J.

Am J Respir Crit Care Med. 1996 Jul;154(1):116-23.

PMID:
8680666
38.

Bartonella (Rochalimaea) quintana endocarditis in an Algerian farmer.

Mainardi JL, Drancourt M, Roland JM, Gestin JL, Raoult D, Acar JF, Goldstein FW.

Clin Microbiol Infect. 1996 Jun;1(4):275-276. No abstract available.

39.

Reappraisal of distal diagnostic testing in the diagnosis of ICU-acquired pneumonia.

Timsit JF, Misset B, Goldstein FW, Vaury P, Carlet J.

Chest. 1995 Dec;108(6):1632-9.

PMID:
7497774
40.

Resistance to ceftriaxone and other beta-lactams in bacteria isolated in the community. The Vigil'Roc Study Group.

Goldstein FW, Péan Y, Gertner J.

Antimicrob Agents Chemother. 1995 Nov;39(11):2516-9.

41.

[beta-Lactamases of Branhamella catarrhalis and their phenotypic implications].

Chaïbi EB, Mugnier P, Kitzis MD, Goldstein FW, Acar JF.

Res Microbiol. 1995 Nov-Dec;146(9):761-71. Review. French.

PMID:
8584798
42.
43.

Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis.

Mainardi JL, Gutmann L, Acar JF, Goldstein FW.

Antimicrob Agents Chemother. 1995 Sep;39(9):1984-7. Erratum in: Antimicrob Agents Chemother 1995 Dec;39(12):2835.

44.

Epidemiology of antibiotic resistance in Haemophilus influenzae.

Goldstein FW, Acar JF.

Microb Drug Resist. 1995 Summer;1(2):131-5. Review.

PMID:
9158746
45.

SYN987, SYN1193, and SYN1253, new quinolones highly active against gram-positive cocci.

Kitzis MD, Goldstein FW, Ishida N, Acar JF.

J Antimicrob Chemother. 1995 Jul;36(1):209-13.

PMID:
8537267
46.

Native valve endocarditis due to nutritionally variant Streptococcus adjacens associated with Enterococcus faecium.

Nguyen Van JC, Lesprit P, Varon E, Buu-Hoï A, Goldstein FW, Acar J.

Eur J Clin Microbiol Infect Dis. 1995 Jul;14(7):626-7. No abstract available.

PMID:
7588853
47.

Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus.

Mainardi JL, Shlaes DM, Goering RV, Shlaes JH, Acar JF, Goldstein FW.

J Infect Dis. 1995 Jun;171(6):1646-50.

PMID:
7769310
48.

Epidemiology of quinolone resistance: Europe and North and South America.

Goldstein FW, Acar JF.

Drugs. 1995;49 Suppl 2:36-42. Review.

PMID:
8549361
49.
50.

Screening for extended-spectrum cephalosporin resistance in Streptococcus pneumoniae.

Goldstein FW, Kitzis MD, Acar JF.

J Antimicrob Chemother. 1994 Dec;34(6):1076-7. No abstract available.

PMID:
7730226

Supplemental Content

Loading ...
Support Center